The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
|Videos|December 11, 2020
Management of high-risk NMIBC: Options for treatment expand
Author(s)Urology Times staff
“As urologists, we all need to start speaking in risk stratification criteria,” says Katie Murray, DO.
Advertisement
In this video, Katie Murray, DO, shares her takeaways from a discussion at the 2020 Society of Urologic Oncology annual meeting titled, Optimizing Management of High Risk NMIBC – Case-Based Discussion, for which she served as a panelist. Murray is an assistant professor of surgery-urology at the University of Missouri, Columbia.
Advertisement
Related to this article
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.
Advertisement
Advertisement
Trending on Urology Times
1
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
2
Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC
3
LITESPARK-012: Lessons from a negative phase 3 trial in first-line RCC
4
Belzutifan plus lenvatinib maintains PFS benefit vs cabozantinib in advanced ccRCC
5